January 5, 2024
In this Q&A with Drug Target Review, Pheast Therapeutics’ cofounder and CSO (now CEO), Roy Maute unveils the company’s focus on the CD24 macrophage target to reactivate the anti-cancer immune response, harnessing the innate biology of macrophage checkpoint inhibitors and suppressing “don’t eat me” signals to drive therapeutic efficacy in solid tumors.
Read the full article online here.